We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) closed at $69.82 in the latest trading session, marking a +1.16% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.11%. At the same time, the Dow added 0.91%, and the tech-heavy Nasdaq lost 0.82%.
Shares of the drugmaker have depreciated by 5.23% over the course of the past month, underperforming the Medical sector's gain of 1.66%, and the S&P 500's gain of 5.17%.
The investment community will be closely monitoring the performance of Novo Nordisk in its forthcoming earnings report. In that report, analysts expect Novo Nordisk to post earnings of $0.91 per share. This would mark year-over-year growth of 40%. Our most recent consensus estimate is calling for quarterly revenue of $11.83 billion, up 20.47% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.9 per share and a revenue of $50.07 billion, signifying shifts of +18.9% and +18.94%, respectively, from the last year.
Any recent changes to analyst estimates for Novo Nordisk should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 1.56% rise in the Zacks Consensus EPS estimate. At present, Novo Nordisk boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 17.72. For comparison, its industry has an average Forward P/E of 13.9, which means Novo Nordisk is trading at a premium to the group.
Meanwhile, NVO's PEG ratio is currently 1.23. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.23 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 97, placing it within the top 40% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Novo Nordisk (NVO - Free Report) closed at $69.82 in the latest trading session, marking a +1.16% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.11%. At the same time, the Dow added 0.91%, and the tech-heavy Nasdaq lost 0.82%.
Shares of the drugmaker have depreciated by 5.23% over the course of the past month, underperforming the Medical sector's gain of 1.66%, and the S&P 500's gain of 5.17%.
The investment community will be closely monitoring the performance of Novo Nordisk in its forthcoming earnings report. In that report, analysts expect Novo Nordisk to post earnings of $0.91 per share. This would mark year-over-year growth of 40%. Our most recent consensus estimate is calling for quarterly revenue of $11.83 billion, up 20.47% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.9 per share and a revenue of $50.07 billion, signifying shifts of +18.9% and +18.94%, respectively, from the last year.
Any recent changes to analyst estimates for Novo Nordisk should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 1.56% rise in the Zacks Consensus EPS estimate. At present, Novo Nordisk boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 17.72. For comparison, its industry has an average Forward P/E of 13.9, which means Novo Nordisk is trading at a premium to the group.
Meanwhile, NVO's PEG ratio is currently 1.23. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.23 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 97, placing it within the top 40% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.